Bone Tumor – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Bone Tumor – Drugs In Development, 2024 report and make more profitable business decisions.
Bone Tumor or bone cancer affecting any bone in the body. Most of the bone cancers are benign while some are malignant or cancerous. This occurs when bone cells divide uncontrollably. Osteosarcoma, Ewing sarcoma, chondrosarcoma are the types of sarcomas. Most commonly occurs in children than in adults. Etiology is idiopathic. Pain in bones, swelling, fatigue, fever, weight loss are some common symptoms. Radiographic findings with X-ray, MRI, CT-scan, biopsy and other required tests are performed to diagnose the condition. Benign tumors can be managed with symptomatic medications, while for malignant chemotherapy, radiation therapy and eventually in severe cases surgery is chosen. Bone cancer can be metastatic and spreads to breast, lungs, thyroid, renal, pancreas.
The Bone Tumor drugs in development market research report provide comprehensive information on the therapeutics under development for Bone Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Tumor and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Bone Tumor | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Bone Tumor therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Bone Tumor pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bone Tumor treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
CSPC Pharmaceutical Group LtdEden Biologics Inc
Genor BioPharma Co Ltd
Iovance Biotherapeutics Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
NeuClone Pty Ltd
Sandoz Group AG
Shanghai Henlius Biotech Inc
Surv BioPharma Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Bone Tumor reports